Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

DEA Schedule I/Schedule II 1992 production quotas

  • News

Executive Summary

DEA's list for 1992 contains proposed quotas for 36 Schedule II controlled substances and 10 Schedule I controlled drugs. For the Schedule II drug, hydrocodone, DEA proposed a production level of 3,891,000 grams, 220,000 grams less than the antitussive/analgesic's 1991 quota ("The Pink Sheet" Feb. 4, In Brief). The 1992 quota for another Schedule II drug, fentanyl is 48,500 grams, 2,000 grams more than the drug's 1991 level. The proposed quota provides for 4,937,000 grams of morphine (for sale), 929,000 grams more than the amount in 1991, and allows for 63,726,000 grams of codeine (for sale), 6,819,000 grams more than in 1991. The DEA announced the proposed quotas in the Aug. 8 Federal Register.

Table

View full table

Tags:
Latest Headlines

Wegovy's Medicare Part D Prospects: Four Million Lives And Counting?

ICER Debuts Clinical Trial Diversity Assessment Framework

US FDA Wants Advice About Advisory Committees: Try Having Some?

Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives

See All
UsernamePublicRestriction

Register

PS019563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By